The global immunization alliance Gavi and partner organization UNICEF have negotiated a 25 percent cost reduction for the Serum Institute of India's R21 malaria vaccine, lowering each dose from approximately four dollars to $2.99 within the coming year. The arrangement will generate $90 million in savings over five years, enabling vaccination programs to procure 30 million additional doses and protect 7 million more children across vulnerable populations.
The announcement arrives as Gavi faces mounting financial pressures after falling $3 billion short of fundraising goals earlier this year, with major contributors like the United States redirecting resources elsewhere. Malaria continues killing over 500,000 people annually, predominantly young children throughout sub-Saharan Africa, making the vaccine's accessibility particularly significant.
Complete protection against the disease requires four injections per child, bringing total treatment costs to $11.96 under the revised pricing structure. GSK manufactures the alternative malaria vaccine at roughly ten dollars per dose, though Bharat Biotech has committed to cutting that figure by half when assuming production responsibilities in 2028.
The announcement arrives as Gavi faces mounting financial pressures after falling $3 billion short of fundraising goals earlier this year, with major contributors like the United States redirecting resources elsewhere. Malaria continues killing over 500,000 people annually, predominantly young children throughout sub-Saharan Africa, making the vaccine's accessibility particularly significant.
Complete protection against the disease requires four injections per child, bringing total treatment costs to $11.96 under the revised pricing structure. GSK manufactures the alternative malaria vaccine at roughly ten dollars per dose, though Bharat Biotech has committed to cutting that figure by half when assuming production responsibilities in 2028.
